Beacon Therapeutics is an innovative ophthalmic gene therapy brand focused on restoring and enhancing the vision of patients suffering from various retinal diseases that lead to blindness. With a strong scientific foundation, the company offers a late-stage development candidate for treating X-linked retinitis pigmentosa (XLRP). Additionally, Beacon Therapeutics has two promising preclinical programs, one targeting dry age-related macular degeneration (AMD) and another, in-licensed from the University of Oxford, aimed at cone-rod dystrophy (CRD).

What sets Beacon Therapeutics apart is its cutting-edge target generation technology platform that enables the identification, screening, and search for secreted proteins within the ophthalmology space. Backed by Syncona and other prominent investors, including Oxford Science Enterprises, the brand is well-positioned to revolutionize the field of ophthalmic gene therapy. At the helm of Beacon Therapeutics is a seasoned leadership team, boasting years of experience in both gene therapy and ophthalmology.

Led by Chief Executive Officer David Fellows, Chief Medical Officer Dr. Nadia Waheed, Chief Scientific Officer Dr. Abraham Scaria, and Senior Vice President of Technical Operations Eduardo Jacobo, this dedicated team is committed to making a profound difference in the lives of patients.

With its unwavering focus on innovation and patient-centric approach, Beacon Therapeutics is set to redefine the future of ophthalmic gene therapy